XBIT - XBiotech Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

5.47

+0.07

(+1.39%)

At close: 04:00PM EDT

Stock chart is not supported by your current browser

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

Double Moving Average Crossover

Performance Outlook

Short Term
2W - 6W
Mid Term
6W - 9M
Long Term
9M+

Previous Close	5.39
Open	5.48
Bid	5.20 x 800
Ask	5.93 x 1800
Day's Range	5.10 - 5.74
52 Week Range	3.00 - 6.49
Volume	125,027
Avg. Volume	74,767

Market Cap	166.503M
Beta (5Y Monthly)	1.21
PE Ratio (TTM)	N/A
EPS (TTM)	-1.11
Earnings Date	Aug 07, 2023 - Aug 11, 2023
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	Jul 15, 2021
1y Target Est	N/A

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for XBIT

Learn more

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

All

GlobeNewswire
FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis Patients
XBiotech Believes its Drug Candidate Natrunix Could Revolutionize Arthritis TreatmentAUSTIN, Texas, May 22, 2023 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) today reports that the FDA’s Division of Rheumatology has authorized the Company to initiate a Phase II clinical study to test Natrunix™ as a treatment for Rheumatoid Arthritis. The randomized, double-blind, placebo-controlled, trial will examine the effectiveness of Natrunix to treat rheumatoid arthritis compared to placebo in subjects
GlobeNewswire
XBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its Shares
AUSTIN, Texas, May 17, 2023 (GLOBE NEWSWIRE) -- Xbiotech Inc. (NASDAQ: XBIT) (“Xbiotech”) announced today that it commenced a “modified Dutch auction” issuer tender offer to purchase up to $80,000,000 in value of its common shares, or such lesser number of common shares as are properly tendered and not properly withdrawn, at a price not greater than $4.00 nor less than $3.80 per common share, to the seller in cash, less any applicable withholding taxes and without interest (the “Offer”). The Off
GlobeNewswire
XBiotech Announces First Subject Enrollment in Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke
Hutrukin, A Therapy Discovered and Manufactured at XBiotech, Is Aimed to Reduce Brain Injury after StrokeAUSTIN, Texas, April 17, 2023 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) has enrolled the first subject in a randomized, open-label, placebo-controlled dose escalation clinical study to evaluate safety and pharmacokinetics of Hutrukin. Hutrukin is being developed as a novel treatment to reduce brain injury following ischemic stroke. There are more than 10 million ischemic strokes each y
Simply Wall St.
XBiotech Inc.'s (NASDAQ:XBIT) top owners are individual investors with 51% stake, while 36% is held by insiders
Key Insights The considerable ownership by individual investors in XBiotech indicates that they collectively have a...
Simply Wall St.
The past three years for XBiotech (NASDAQ:XBIT) investors has not been profitable
Every investor on earth makes bad calls sometimes. But you want to avoid the really big losses like the plague. So take...
Simply Wall St.
XBiotech (NASDAQ:XBIT) Is In A Good Position To Deliver On Growth Plans
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Simply Wall St.
XBiotech Third Quarter 2022 Earnings: US$0.42 loss per share (vs US$0.11 loss in 3Q 2021)
XBiotech ( NASDAQ:XBIT ) Third Quarter 2022 Results Key Financial Results Net loss: US$12.7m (loss widened by 288% from...
Simply Wall St.
Insiders own 35% of XBiotech Inc. (NASDAQ:XBIT) shares but individual investors control 47% of the company
If you want to know who really controls XBiotech Inc. ( NASDAQ:XBIT ), then you'll have to look at the makeup of its...
GlobeNewswire
XBiotech Announces First Patient Enrolled into the French National Cancer Institute (INCA) Sponsored Phase I/II/III Clinical Study for Natrunix™ Therapy for Colorectal Cancer
INCA funded Phase I/II/III Study for Natrunix in Combination with Trifluridine/Tipiracil, the TASKIN Study, Launches at 20 Leading Medical Centers in FranceAUSTIN, Texas, Oct. 13, 2022 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced today the enrollment of the first patient in a multicenter, randomized clinical study for Natrunix in combination with trifluridine/tipiracil for the treatment of colorectal cancer. The much anticipated clinical study for XBiotech’s candidate cancer treatment i
Simply Wall St.
XBiotech (NASDAQ:XBIT) shareholders have endured a 73% loss from investing in the stock a year ago
As every investor would know, you don't hit a homerun every time you swing. But it would be foolish to simply accept...
Simply Wall St.
We Think XBiotech (NASDAQ:XBIT) Can Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
GlobeNewswire
XBiotech Announces Successful Completion of Phase I portion of Pancreatic Cancer Study
Novel Natrunix Treatment Shows Promise in Combination Chemotherapy for Treatment of Pancreatic CancerAUSTIN, Texas, June 20, 2022 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today it successfully completed the Phase I portion of its 1-BETTER study, a Phase I/II randomized, double-blind, placebo-controlled clinical study to evaluate its anti-cancer drug Natrunix in combination with chemotherapy for treating pancreatic cancer. Enrollment in the Phase II portion is commencing immedia